ArticleMethods in molecular biology (Clifton, N.J.)2026
Biosensors for Cancer and Inflammation: Whole-Cell Biosensors for Soluble Molecules.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biosensors are devices leveraging biological modules for the detection of molecules of interest, including biomarkers of inflammation and cancer. Using elements capable of detecting small molecules, such as transcription factors, aptamers, and antibodies, they specifically and sensitively interact with a target analyte, producing a detectable response. By applying traditional and synthetic biology approaches, these modules can be engineered to detect different molecules. A whole-cell biosensor (WCB) is a subtype of biosensor in which a whole living organism with an active metabolism is used to detect a compound. WCBs based on synthetic transcription factors are adaptable and accessible sensing tools for the detection of small soluble molecules. In this chapter, we describe a pipeline for the construction of a prokaryotic biosensor strain bearing a genetic circuit that integrates a custom-made transcription factor. As an example, we use the strain Escherichia coli MG1655 (pCKT-Sphnx, pHC_DYO-LacI-R), which has been engineered to detect neuraminic acid, an oral cancer biomarker present in saliva.
Indexed as
Identifiers
41478986What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.